A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Inclusion Criteria

• Age at least 18 years.
• Documented evidence of NSCLC (locally advanced, unresectable, Stage III)
• Patients must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy.
• World Health Organisation (WHO) Performance Status of 0 to 1.
• Estimated life expectancy of more than 12 weeks.

Exclusion Criteria

• Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
• Active or prior autoimmune disease or history of immunodeficiency.
• Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
• Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
• Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy.
• Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).